Beyond Air, Inc. (XAIR) News
Filter XAIR News Items
XAIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XAIR News Highlights
- For XAIR, its 30 day story count is now at 3.
- Over the past 12 days, the trend for XAIR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NOV and SITC are the most mentioned tickers in articles about XAIR.
Latest XAIR News From Around the Web
Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare ConferenceGARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic |
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond Cancer presents positive first-in-human data for intratumoral administration of ultra-high concentration nitric oxide (UNO) therapy demonstrating safety and evidence of immune system activation at the Society for Immunotherapy Conference (SITC) Submitted PMA supplement to FDA for the expansion of Lun |
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingFirst-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously observed in preclinical studies Data represent the first successful administration of intratumoral UNO therapy Additional Phase 1 data for UNO expected in 2024 GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, I |
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and WebcastCall scheduled for Monday, November 13th at 4:30 pm Eastern TimeGARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), tod |
Beyond Air® To Participate in the Truist Securities BioPharma SymposiumGARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic |
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in MiceFigure 1 PD-L1 Upregulation in CT26 and 4T1 Cells after In Vitro Exposure to UNO Figure 2 T-cell profiling in tumors of CT26 mice treated with UNO Figure 3 Myeloid cell profiling in CT26 tumors treated with UNO UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with initial data expected to be released on November 3rd at the Society for Immunotherapy of Cancer ( |
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination studies of 50,000 or 100,000 ppm UNO with anti-mPD-1 demonstrated more than a doubling in survival at Day 75 versus anti-mPD-1 alone Initial data from a Phase 1a, first-in-human study to be presented at the Society for Immunotherapy in Cancer (SITC) on November 3, 2023 GARDEN CITY, N.Y. and HAMILTON, Bermuda |
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PHContract awarded for products that bring improvement to health care industryGARDEN CITY, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today an |
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Co |
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceGARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that the Company will present a corporate overview and participate in |